Periodontal health and serum, saliva matrix metalloproteinases in patients with mild chronic obstructive pulmonary disease

Journal of Periodontal Research

Volumn 48, Issue 3, 2013, Pages 269-275

  Yildirim, E ^a   Kormi, I ^b,c   Başoǧlu, Ö K ^a   Gurgun A ^a   Kaval, B ^a   Sorsa, T ^c   Buduneli, N ^a  

^a EGE UNIVERSITY   (Turkey)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Chronic obstructive pulmonary disease; Matrix metalloproteinases; Periodontal disease; Saliva; Serum; Tissue inhibitor of matrix metalloproteinases 1

Indexed keywords

COLLAGENASE 3; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC PERIODONTITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; MALE; MIDDLE AGED; NONPARAMETRIC TEST; SALIVA; SPIROMETRY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHRONIC PERIODONTITIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MALE; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 8; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SALIVA; SPIROMETRY; STATISTICS, NONPARAMETRIC; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84876796555     PISSN: 00223484     EISSN: 16000765     Source Type: Journal    
DOI: 10.1111/jre.12004     Document Type: Article

References (38)

1. Ebersole JL, Capelli D. Acute-phase reactants in infections and inflammatory diseases. Periodontol 2000 2000;23:19-49.
2. Didilescu AC, Skaug N, Marica C, Didilescu C. Respiratory pathogens in dental plaque of hospitalized patients with chronic lung diseases. Clin Oral Investig 2005;9:141-147.
3. Hayes C, Sparrow D, Cohen M, Vokonas PS, Garcia RI. The association between alveolar bone loss and pulmonary function: the VA Dental Longitudinal Study. Ann Periodontol 1998;3:257-261.
4. Scannapieco FA, Papandonatos GD, Dunford RG. Associations between oral conditions and respiratory disease in a national sample survey population. Ann Periodontol 1998;3:251-256.
5. Scannapieco FA, Ho AW. Potential associations between chronic respiratory disease and periodontal disease: analysis of National Health and Nutrition Examination Survey III. J Periodontol 2001;72:50-56.
6. Leuckfeld I, Obregon-Whittle MV, Lund MB, Geiran O, Bjortuft O, Olsen I. Severe chronic obstructive pulmonary disease: association with marginal bone loss in periodontitis. Respir Med 2008;102:488-494.
7. Birkedal-Hansen H. Role of cytokines and inflammatory mediators in tissue destruction. J Periodontal Res 1993;28:500-510.
8. Ryan ME, Ramamurthy NS, Golub LM. Matrix metalloproteinases and their inhibition in periodontal treatment. Curr Opin Periodontol 1996;3:85-86.
9. Sorsa T, Tjaderhane L, Konttinen YT, et al. Matrix metalloproteinases: contribution to pathogenesis and treatment of periodontal inflammation. Ann Med 2006;38:306-321.
10. Kuula H, Salo T, Pirilä E, et al. Local and systemic responses in matrix metalloproteinase 8-deficient mice during Porphyromonas gingivalis-induced periodontitis. Infect Immun 2009;77:850-859.
11. Demkow U, van Overveld FJ. Role of elastases in the pathogenesis of chronic obstructive pulmonary disease: implications for treatment. Eur J Med Res 2010;15(suppl 2):27-35.
12. Vernooy JH, Lindeman JH, Jacobs JA, et al. Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD. Chest 2004;126:1082-1010.
13. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Available at: http://www.goldcopd.org/. (accessed on 15 September 2011).
14. Hanemaaijer R, Sorsa T, Konttinen YT, et al. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor-alpha and doxycycline. J Biol Chem 1997;273:1504-1509.
15. Tuomainen AM, Nyyssonen K, Laukkanen JA, et al. Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men. Arterioscler Thromb Vasc Biol 2007;27:2722-2728.
16. Sorsa T, Mäntylä P, Rönkä H, et al. Scientific basis of matrix metalloproteinase-8 specific chair-side test for monitoring periodontal and peri-implant health and disease. Ann N Y Acad Sci 1999;878:130-140.
17. Rautelin HI, Oksanen AM, Veijola LI, et al. Enhanced systemic matrix metalloproteinase response in Helicobacter pylori gastritis. Ann Med 2009;41:208-215.
18. Miller CS, King CP, Langub MC, Kryscio RJ, Thomas MV. Salivary biomarkers of existing periodontal disease. A cross-sectional study. J Am Dent Assoc 2006;137:322-329.
19. Sorsa T, Hernández M, Leppilahti J, Munjal S, Netuschil L, Mäntylä P. Detection of gingival crevicular fluid MMP-8 levels with different laboratory and chair-side methods. Oral Dis 2010;16:39-45.
20. Deo V, Bhongade ML, Ansari S, Chavan RS. Periodontitis as a potential risk factor for chronic obstructive pulmonary disease: a retrospective study. Indian J Dent Res 2009;20:466-470.
21. Wang Z, Zhou X, Zhang J et al. Periodontal health, oral health behavious, and chronic obstructive pulmonary disease. J Clin Periodontol 2009;36:750-755.
22. Liu Z, Zhang W, Zhang J, et al. Oral hygiene, periodontal health and chronic obstructive pulmonary disease exacerbations. J Clin Periodontol doi: 10.1902/jop.110472.
23. Si Y, Fan H, Song Y, Zhou X, Zhang J, Wang Z. Association between periodontitis and chronic obstructive pulmonary disease (COPD) in a Chinese population. J Periodontol 2012;39:45-52.
24. Hyman JJ, Reid BC. Cigarette smoking, periodontal disease, and chronic obstructive pulmonary disease. J Periodontol 2004;75:9-15.
25. Zhou X, Wang Z, Song Y, Zhang J, Wang C. Periodontal health and quality of life in patients with chronic obstructive pulmonary disease. Respir Med 2011;105:67-73.
26. Scannapieco FA, Genco RJ. Association of periodontal infections with atherosclerotic and pulmonary diseases. J Periodontal Res 1999;34:340-345.
27. Bentley DW. Bacterial pneumonia in the elderly: clinical features, diagnosis, etiology, and treatment. Gerontology 1984;30:297-307.
28. Estes RJ, Meduri GU. The pathogenesis of ventilator- associated pneumonia: mechanisms of bacterial translocation and airway inoculation. Intensive Care Med 1995;21:365-383.
29. Toews GB. Nosocomial pneumonia. Am J Med Sci 1986;291:355-367.
30. Zhou X, Han J, Song Y, Zhang J, Wang Z. Serum levels of 25-hydroxyvitamin D, oral health, and chronic obstructive pulmonary disease. J Clin Periodontol 2012;39:350-356.
31. Vignola AM, Riccobono L, Mirabella A, et al. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med 1998;158:1945-1950.
32. Culpitt SV, Rogers DF, Traves SL, Barnes PJ, Donnelly LE. Sputum matrix metalloproteases: comparison between chronic obstructive pulmonary disease and asthma. Respir Med 2005;99:703-710.
33. Russell E, Culpitt SV, De Matos C, et al. Release and activity of MMP-9 and TIMP-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002;26:602-609.
34. Ilumets H, Rytilä P, Demedts I, et al. Matrix metalloproteinases -8, -9 and -12 in smokers and patients with stage 0 COPD. Int J Chron Obstruct Pulmon Dis 2007;2:369-379.
35. Belvisi MG, Bottomley KM. The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs? Inflamm Res 2003;52:95-100.
36. Turino GM. Proteases in COPD: a critical pathway to injury. Chest 2007;132:1724-1725.
37. Higashimoto Y, Iwata T, Okada M, Satoh H, Fukuda K, Tohda Y. Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. Respir Med 2009;103:1231-1238.
38. de Torres JP, Casanova C, Pinto-Plata V, et al. Gender differences in plasma biomarker levels in a cohort of COPD patients: a pilot study. PLoS ONE 2011;6(1):e16021.